The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
Kevin Sharpe(Institute of Cancer Research), Tom Powles(Queen Mary University of London), Marie O’Donnell(Birmingham Women’s and Children’s NHS Foundation Trust), Fiach C. O’Mahony(Edinburgh Cancer Research), Elaine Y. Wan(NewYork–Presbyterian Hospital), Ekaterini Boleti(Royal Free London NHS Foundation Trust), Christophe Van Neste(King Abdullah University of Science and Technology), Wim Van Criekinge(Ghent University Hospital), Neil R. Smith(Institute of Cancer Research), Luis Beltrán(Queen Mary University of London), Colan Ho-Yen(Institute of Cancer Research), Yong‐Jie Lu(Queen Mary University of London), David J. Harrison(NHS Lothian), Tim De Meyer(Ghent University), Axel Bex(The Royal Free Hospital), Dawn Baker(Institute of Cancer Research), Alan Mackay(Institute of Cancer Research), Daniel M. Berney(Queen Mary University of London), Anju Sahdev(St Bartholomew's Hospital), Grant D. Stewart(University of Cambridge), Marco Gerlinger(St Bartholomew's Hospital), Andrew R. Reynolds(Breast Cancer Now), Simon Chowdhury(Sarah Cannon Research Institute), Charlotte Rofe(Institute of Cancer Research), Barry R. Davies(Immodulon Therapeutics (United Kingdom)), Rukma Doshi(Institute of Cancer Research), Irfan Kayani(Institute of Cancer Research)
Cited by 69
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
|European Journal of Endocrinology|2016|1.5k